Arcutis Biotherapeutics, Inc. (ARQT)
23.85
+0.10
(+0.42%)
USD |
NASDAQ |
Sep 02, 16:00
23.70
-0.15
(-0.63%)
Pre-Market: 08:13
Arcutis Biotherapeutics Research and Development Expense (TTM) : 91.04M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 91.04M |
| March 31, 2026 | 90.14M |
| December 31, 2025 | 77.05M |
| September 30, 2025 | 71.08M |
| June 30, 2025 | 70.98M |
| March 31, 2025 | 70.82M |
| December 31, 2024 | 76.42M |
| September 30, 2024 | 85.72M |
| June 30, 2024 | 92.45M |
| March 31, 2024 | 98.37M |
| December 31, 2023 | 110.58M |
| September 30, 2023 | 120.68M |
| June 30, 2023 | 164.17M |
| March 31, 2023 | 177.16M |
| December 31, 2022 | 182.44M |
| Date | Value |
|---|---|
| September 30, 2022 | 201.12M |
| June 30, 2022 | 171.99M |
| March 31, 2022 | 164.55M |
| December 31, 2021 | 145.56M |
| September 30, 2021 | 120.37M |
| June 30, 2021 | 112.51M |
| March 31, 2021 | 111.76M |
| December 31, 2020 | 115.31M |
| September 30, 2020 | 98.69M |
| June 30, 2020 | 78.30M |
| March 31, 2020 | 55.50M |
| December 31, 2019 | 36.52M |
| September 30, 2019 | 31.11M |
| June 30, 2019 | 25.84M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Insmed, Inc. | 860.84M |
| Emergent BioSolutions, Inc. | 45.30M |
| Exelixis, Inc. | 824.32M |
| Vertex Pharmaceuticals, Inc. | 3.907B |